Literature analysis of Acanthopanax XXXX in China.

@entity1 @entity566 @entity65 @entity2021
UNASSIGNED: The aims of this study are to investigate the occurrence characteristics of Acanthopanax ( c   w   ji  ) @entity2021 and to provide objective evidence for the rational use of the medicine. Fifty-seven cases of Acanthopanax @entity2021 were collected from several professional databases in China. The statistical data of the @entity1 were analyzed with Visual FoxPro 6.0 and Office Excel 2003 by Microsoft (Redmond, WA, USA). The male:female incidence ratio was 0.5:1. Fifty-six (98.25%) @entity1 were older than 30 years. Thirty-nine (68.42%) @entity1 had an unknown @entity566 history. Nine (15.79%) @entity1 used Acanthopanax for unlabeled indications. In most (98.25 %) @entity1 , Acanthopanax was used in the form of dosage injection. @entity2021 occurred within 30 minutes after treatment in 52 (94.54%) @entity1 , and all episodes occurred during the infusion process. In two (3.51%) @entity1 , the episode occurred when they used Acanthopanax for the second time. In one (1.75%) @entity1 , the episode occurred during the third time of use. The clinical symptoms of @entity2021 are diversified, but all @entity1 presented with @entity65 . Acanthopanax injections that led to @entity2021 were produced exclusively by four manufacturers. Four (7.02%) @entity1 died and 49 (85.96%) @entity1 were cured, but the status of four @entity1 is unknown. Because an Acanthopanax injection may cause @entity2021 and can be fatal in severe cases, physicians and @entity1 must pay close attention to using it rationally. Clinicians should carefully consult the allergic constitution of their @entity1 , strictly follow the guidelines of the drug, use Acanthopanax in the oral dosage form as much as possible, and strengthen therapeutic monitoring.
